219 related articles for article (PubMed ID: 30710723)
1. Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study.
Huang Y; Chow KKH; Aredo JV; Padda SK; Han SS; Kakusa BW; Hayden Gephart M
World Neurosurg; 2019 May; 125():e487-e496. PubMed ID: 30710723
[TBL] [Abstract][Full Text] [Related]
2. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
[TBL] [Abstract][Full Text] [Related]
3. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
Zhu Q; Sun Y; Cui Y; Ye K; Yang C; Yang D; Ma J; Liu X; Yu J; Ge H
Oncotarget; 2017 Feb; 8(8):13304-13311. PubMed ID: 28076323
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
6. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
8. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
9. Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
Vaca SD; Connolly ID; Ho C; Neal J; Hayden Gephart M
Neurosurgery; 2018 Jan; 82(1):E6-E14. PubMed ID: 28945866
[TBL] [Abstract][Full Text] [Related]
10. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
11. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
13. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
14. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
16. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
17. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
[TBL] [Abstract][Full Text] [Related]
19. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
[TBL] [Abstract][Full Text] [Related]
20. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
[No Abstract] [Full Text] [Related]
[Next] [New Search]